Capital Markets & Financing
Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases
BOSTON and SHANGHAI, June 11, 2023 /PRNewswire/ -- Eccogene Inc., a clinical-stage biotechnology company developing innovative therapeutic solutions for metabolic diseases, today announced a CNY 180 million (about $25 million) Series B financing.
CLSA Becomes HKEX-approved HKD-RMB Dual Counter Market Maker
CLSA Limited (“CLSA”) is pleased to become one of the first batch Dual Counter Market Makers (“DCMMs”) under the HKD-RMB Dual Counter Model (“Dual Counter Model”) by Hong Kong Exchanges and Clearing Limited (“HKEX”).
Kelun Biotech Begins Pre-Marketing Activities for Hong Kong IPO
A biotech subsidiary of Sichuan Kelun Pharmaceutical has reportedly started pre-marketing activities for its Hong Kong initial public offering, aiming to raise up to US$400 million (HK$3.12 billion), after it was given the green light from regulators to list in the city on Sunday
Credit Suisse puts up China brokerage venture for sale
Credit Suisse and a joint venture partner are seeking buyers for their China securities brokerage business due to the Swiss bank's takeover by rival UBS
Acepodia Secures $100 Million Series D Financing to Advance First-in-Class Cell Therapies with Antibody-Cell Conjugation (ACC) Platform
Acepodia announced a $100 million Series D financing led by Digital Mobile Venture with participation from additional existing investors.
LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune Diseases
LTZ Therapeutics – an immunotherapy-focused biotech company – today announced it has raised over $10 million in pre-A+ financing led by Qiming Venture Partners, with co-investor participation from Shunwei Capital, Lihehongxin Venture Capital Partnership and K2 Venture Partners.
Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan
HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, May 17, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has received approval of an HK$8 million subsidy from the Hong Kong Science and Technology Parks Corporation ("HKSTP"), which will be used to accelerate research and development of its leading RNAi drug candidate, STP122G, a GalNAc-based innovative anticoagulant therapeutic.
ChomiX Biotech Announces Millions of Dollars Series Pre-A+ Financing to Accelerate the Development of Chemoproteomics Platform
NANJING, China, May 15, 2023 /PRNewswire/ -- Recently, ChomiX Biotech Co., Ltd. (hereinafter referred to as ChomiX), a leading biotechnology company focusing on the preclinical development of innovative small molecule drugs, announced the completion of millions of dollars Pre-A+ Financing by TigerYeah Capital,old shareholder Tsinghua Innovation Ventures, and Morning Spring Venture.
Drug Farm Raises $27M USD Financing for Advancement of First-In-Class Hepatitis B and Cardiovascular-Renal Drugs into Clinical Trials
GUILFORD, Conn. & SHANGHAI--(BUSINESS WIRE)--Drug Farm, a private biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, has raised the first round of C series financing totaling $27 million USD.
China SXT Pharmaceuticals, Inc. Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule
TAIZHOU, China, May 10, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that on May 4, 2023, the Company received a written notification from the Nasdaq's Listing Qualifications Department, granting the Company another 180 calendar days extension, or until October 30, 2023, to regain compliance with Nasdaq’s minimum bid price requirement.
